Enhanced dendritic cell antigen presentation in RNA-based immunotherapy

Journal of Surgical Research

Volumn 105, Issue 1, 2002, Pages 17-24

  Kalady, Matthew F ^a   Onaitis, Mark W ^a   Padilla, Karen M ^a   Emani, Sirisha ^a   Tyler, Douglas S ^a   Pruitt, Scott K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigen presentation; Dendritic cells; Immunotherapy; mRNA based vaccines

Indexed keywords

DOUBLE STRANDED RNA; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; MELAN A; MESSENGER RNA; RNA;

ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; ELECTROPORATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOTHERAPY; LYMPHOCYTE CLONE; LYMPHOCYTE CULTURE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0036297495     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2002.6435     Document Type: Article

References (43)

1. Dendritic cells and the control of immunity
2. The dendritic cell system and its role in immunogenicity
3. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
4. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
5. Immunotherapy of cancer with dendritic-cell-based vaccines
6. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
7. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes using human dendritic cells transfected with RNA
8. Costimulation of T cell growth
9. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor capacity
10. Differential activation through the TCR-CD3 complex affects the requirement for costimulation of human T cells
11. T cell activation determined by T cell receptor number and tunable thresholds
12. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
13. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses
14. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors
15. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
16. Dendritic cells: Unique leukocyte populations which control the primary immune response
17. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
18. Phagocytosis of antigens by Langerhans cells in vitro
19. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
20. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
21. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation
22. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells
23. HLA class I molecule expression is upregulated during maturation of dendritic cells, protecting them from natural killer cell-mediated lysis
24. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
25. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
26. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
27. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
28. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable
29. Expression of CCR-7, MIP-3B, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities
30. Both degree and timing of maturation of dendritic cells are critical for optimal T cell presenting capacity
31. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD 8(+) T lymphocyte responses
32. Tumor vaccine strategies that employ dendritic cells and tumor lysates: Experimental and clinical studies
33. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
34. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated
35. Optimization of the sequence of antigen loading and CD40-ligand-induced
36. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a Mart-1 adenovirus
37. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
38. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using human dendritic cells pulsed with RNA
39. Dendritic cells infected with poxviruses encoding MART-1/Mean A sensitize T lymphocytes in vitro
40. Requirements of mature dendritic cells for efficient acitvation of influenza A-specific memory CD 8+ T cells
41. Mature dendritic cells prime functionally superior Melan-A-specific CD 8+ lymphocytes as compared with nonprofessional APC
42. Purified MHC class I and peptide complexes activate naive CD8+ T cells independently of the CD28/B7 and LFA-1/ICAM costimulatory interactions
43. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified total tumor RNA